プロテインキナーゼCシータタイプ治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Protein Kinase C Theta Type - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0392
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Protein Kinase C Theta Type – Pipeline Review, H2 2019
Summary

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report Protein Kinase C Theta Type – Pipeline Review, H2 2019, outlays comprehensive information on the Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) – Protein kinase C theta (PKC-θ) is an enzyme encoded by the PRKCQ gene. It mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-costimulated T-cells, is required for the activation of NF-kappa-B and JUN. It plays an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. It mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1 which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway. The molecules developed by companies in Preclinical and Discovery stages are 3 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Infectious Disease and Metabolic Disorders which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Rheumatoid Arthritis, Autoimmune Disorders, Ewing Sarcoma, Heart Transplant Rejection, Inflammation, Insulin Resistance, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Metastatic Breast Cancer, Obesity, Prostate Cancer and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)
- The report reviews Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects
- The report assesses Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) – Overview
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) – Companies Involved in Therapeutics Development
Astellas Pharma Inc
Bristol-Myers Squibb Co
CompleGen Inc
EpiAxis Therapeutics Pty Ltd
HotSpot Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) – Drug Profiles
AS-2521780 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-90005 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CGX-0471 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CGX-1079 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
englerin A – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPI-110 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PKC-Theta for Inflammation – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Ewing Sarcoma – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PRKCQ for Autoimmune Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) – Dormant Products
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) – Discontinued Products
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) – Product Development Milestones
Featured News & Press Releases
Oct 01, 2017: EpiAxis Therapeutics recruits first Phase 1 patient
Feb 11, 2016: UC launches new cancer therapeutic company
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Astellas Pharma Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by CompleGen Inc, H2 2019
Pipeline by EpiAxis Therapeutics Pty Ltd, H2 2019
Pipeline by HotSpot Therapeutics Inc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

【掲載企業】

Astellas Pharma Inc
Bristol-Myers Squibb Co
CompleGen Inc
EpiAxis Therapeutics Pty Ltd
HotSpot Therapeutics Inc
Takeda Pharmaceutical Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[プロテインキナーゼCシータタイプ治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆